# Pegtibatinase PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pegtibatinase

> The next catalyst for pegtibatinase, sponsored by Travere Therapeutics, Inc. (TVTX), is its primary completion, August 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | pegtibatinase |
| Codes | TVT-058, OT-058, OT-58 |
| Sponsor | Travere Therapeutics, Inc. (TVTX) https://sec-api.dev/companies/tvtx/catalysts |
| Indications | [Homocystinuria](https://sec-api.dev/indications/homocystinuria) |
| Modality |  |
| FDA designations | breakthrough, fast track, orphan |

## Timeline

### May 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 1/2.
- First seen 2025-02-21, last confirmed 2026-11-02.
- SEC Form 10-Q (accession 0001438533-26-000077): "In May 2023, we announced positive topline results from the sixth cohort of the Phase 1/2 COMPOSE Study, which was initiated to inform and refine formulation work for future development and commercial purposes and to further evaluate the dose response curve for pegtibatinase, and to further inform our pivotal development program to ultimately support potential approval of pegtibatinase for the treatment of HCU." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- SEC Form 10-Q (accession 0001438533-26-000077): "For example, the positive nonclinical data we have seen from pegtibatinase being tested in a mouse model of homocystinuria and the positive topline results we reported in December 2021 and May 2023 from the ongoing Phase 1/2 clinical trial of pegtibatinase may not be replicated in future studies." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- SEC Form 10-Q (accession 0001438533-26-000063): "In May 2023, we announced positive topline results from the sixth cohort of the Phase 1/2 COMPOSE Study, which was initiated to inform and refine formulation work for future development and commercial purposes and to further evaluate the dose response curve for pegtibatinase, and to further inform our pivotal development program to ultimately support potential approval of pegtibatinase for the treatment of HCU." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000063/tvtx-20260630.htm
- SEC Form 10-Q (accession 0001438533-26-000063): "For example, the positive nonclinical data we have seen from pegtibatinase being tested in a mouse model of homocystinuria and the positive topline results we reported in December 2021 and May 2023 from the ongoing Phase 1/2 clinical trial of pegtibatinase may not be replicated in future studies." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000063/tvtx-20260630.htm
- SEC Form 10-Q (accession 0001438533-26-000042): "In May 2023, we announced positive topline results from the sixth cohort of the Phase 1/2 COMPOSE Study, which was initiated to inform and refine formulation work for future development and commercial purposes and to further evaluate the dose response curve for pegtibatinase, and to further inform our pivotal development program to ultimately support potential approval of pegtibatinase for the treatment of HCU." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000042/tvtx-20260331.htm
- SEC Form 10-Q (accession 0001438533-26-000042): "For example, the positive nonclinical data we have seen from pegtibatinase being tested in a mouse model of homocystinuria and the positive topline results we reported in December 2021 and May 2023 from the ongoing Phase 1/2 clinical trial of pegtibatinase may not be replicated in future studies." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000042/tvtx-20260331.htm
- SEC Form 10-K (accession 0001438533-26-000014): "In May 2023, we announced positive topline results from the sixth cohort of the Phase 1/2 COMPOSE Study, which was initiated to inform and refine formulation work for future development and commercial purposes and to further evaluate the dose response curve for pegtibatinase, and to further inform our pivotal development program to ultimately support potential approval of pegtibatinase for the treatment of HCU." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm
- SEC Form 10-K (accession 0001438533-26-000014): "Similarly, the positive nonclinical data we have seen from pegtibatinase being tested in a mouse model of homocystinuria and the positive topline results we reported in December 2021 and May 2023 from the ongoing Phase 1/2 clinical trial of pegtibatinase may not be replicated in future studies." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm
- SEC Form 10-Q (accession 0001438533-25-000056): "In May 2023, we announced positive topline results from the sixth cohort of the Phase 1/2 COMPOSE Study, which was initiated to inform and refine formulation work for future development and commercial purposes and to further evaluate the dose response curve for pegtibatinase, and to further inform our pivotal development program to ultimately support potential approval of pegtibatinase for the treatment of HCU." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000056/tvtx-20250930.htm
- SEC Form 10-Q (accession 0001438533-25-000056): "Similarly, the positive nonclinical data we have seen from pegtibatinase being tested in a mouse model of homocystinuria and the positive topline results we reported in December 2021 and May 2023 from the ongoing Phase 1/2 clinical trial of pegtibatinase may not be replicated in future studies." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000056/tvtx-20250930.htm
- SEC Form 10-Q (accession 0001438533-25-000046): "In May 2023, we announced positive topline results from the sixth cohort of the Phase 1/2 COMPOSE Study, which was initiated to inform and refine formulation work for future development and commercial purposes and to further evaluate the dose response curve for pegtibatinase, and to further inform our pivotal development program to ultimately support potential approval of pegtibatinase for the treatment of HCU." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000046/tvtx-20250630.htm
- SEC Form 10-Q (accession 0001438533-25-000046): "Similarly, the positive nonclinical data we have seen from pegtibatinase being tested in a mouse model of homocystinuria and the positive topline results we reported in December 2021 and May 2023 from the ongoing Phase 1/2 clinical trial of pegtibatinase may not be replicated in future studies." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000046/tvtx-20250630.htm

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Homocystinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06247085 (Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06247085

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Homocystinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06247085 (Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06247085

### August 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Homocystinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06431893 (A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06431893

### Aug to Nov 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Homocystinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06431893 (A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06431893

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pegtibatinase.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pegtibatinase PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pegtibatinase

```bibtex
@misc{secapidev_pdufa_pegtibatinase_20261116,
  title        = {Pegtibatinase PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pegtibatinase}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pegtibatinase_20261116","title":"Pegtibatinase PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pegtibatinase","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
